Carregant...
Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
PURPOSE: Oncotype DX (ODX) recurrence score (RS) breast cancer (BC) assay is costly, and performed in only ~1/3 of estrogen receptor (ER)-positive BC patients in the USA. We have now developed a user-friendly nomogram surrogate prediction model for ODX based on a large dataset from the National Canc...
Guardat en:
| Publicat a: | Breast Cancer Res Treat |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer US
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5387031/ https://ncbi.nlm.nih.gov/pubmed/28243897 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4170-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|